Top Markets
Coin of the day
Scopus BioPharma Inc. Scopus BioPharma Inc.

Scopus BioPharma Inc.

SCPS
Rang in Aktien #41540
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical... Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer. The company's offerings include the Duet Platform, which incorporates CpG signal transducer and activator of transcription 3 (STAT3) inhibitors. Another significant product is MRI-1867, a cleverly engineered, orally administered, dual-action hybrid small molecule. MRI-1867 functions as an inverse agonist of the endocannabinoid system's cannabinoid receptor 1 (CB1) and additionally acts as an inhibitor of inducible nitric oxide synthase (iNOS). To advance its key development efforts and other programs, Scopus BioPharma has established strategic collaborations with prominent organizations such as the City of Hope, the National Institutes of Health Program, and The Hebrew University of Jerusalem. Established in 2017, the company was originally named Project18 Inc. before officially rebranding to Scopus BioPharma Inc. in December of that year. Its corporate headquarters are located in New York, New York.
Aktienkurs
$0.0004
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$16.83K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
33.33%
Land
US
Handel Scopus BioPharma Inc. (SCPS)

Kategorie

Kursverlauf für Scopus BioPharma Inc. (SCPS)
Höchster Schlusskurs: $0.00 am 2026-08-01

Niedrigster Schlusskurs: $17.71 am 2020-12-01
Kursverlauf der Aktie von Scopus BioPharma Inc. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.00%
2025 51.79%
2024 -99.40%
2023 -72.25%
2022 -91.18%
2021 -88.82%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.07K -7.40%
KR